Axsome Therapeutics has entered into a settlement agreement with Hikma resolving patent litigation related to Axsome’s product Sunosi (solriamfetol). The litigation, which is pending in the United ...
Axsome Therapeutics AXSM announced that the phase III FOCUS study, which evaluated solriamfetol for the treatment of attention deficit hyperactivity disorder (ADHD), has met its primary and key ...
Shares of IBD 50 stock Axsome Therapeutics tumbled Tuesday after the biotech reported mixed results for its drug, Sunosi, in adults with attention deficit hyperactivity disorder. The company tested ...
NEW YORK, May 09, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders ...
NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, ...
Axsome Therapeutics has reached a settlement agreement with Hetero Labs to resolve a patent dispute related to Hetero Labs’s plans to release a generic of Sunosi, which is a sleep disorder therapy.
NEW YORK, June 28, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) ...
NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results